Torben Plesner
0000-0002-2340-6068
Vejle Hospital
6 papers found
Refreshing results…
Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial
Optimizing the Outcome of Anti-Myeloma Treatment with Daratumumab
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long‐term survival follow‐up from the Phase II study O‐12‐M1
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad?
“Fine‐tuning cytoreduction in resistant multiple myeloma ‐ progress here, too”?
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study
Missing publications? Search for publications with a matching author name.